Skip to main content

CORRECTION article

Front. Endocrinol., 03 September 2020
Sec. Clinical Diabetes
Volume 11 - 2020 | https://doi.org/10.3389/fendo.2020.00649

Corrigendum: Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Jinlida Granules on Metabolic Syndrome in Patients With Abnormal Glucose Metabolism

This article is a correction to:

  1. Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Jinlida Granules on Metabolic Syndrome in Patients With Abnormal Glucose Metabolism

    1. Read original article
\nDe Jin&#x;De Jin1†Lili Hou&#x;Lili Hou2†Shuolong HanShuolong Han2Liping ChangLiping Chang3Huailin Gao,Huailin Gao4,5Yiru ZhaoYiru Zhao1Shenghui ZhaoShenghui Zhao1Xuedong AnXuedong An1Guangyao SongGuangyao Song6Chunli PiaoChunli Piao7Fengmei Lian Fengmei Lian1*Tong Xiao-lin Tong Xiao-lin1*Zhenhua Jia,,, Zhenhua Jia2,3,4,5*
  • 1Department of Endocrinology, Guang'anmen Hospital of China Academy of Chinese Medical Science, Beijing, China
  • 2Department of Cardiovascularology, Key Laboratory of State Administration of TCM (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang, China
  • 3Department of Cardiovascularology, National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang, China
  • 4Department of Cardiovascularology, Key Disciplines of State Administration of TCM for Collateral Disease, Shijiazhuang, China
  • 5National Administration of Traditional Chinese Medicine (TCM) Regional TCM Diagnosis and Treatment Center (Cardiovascular Disease), Shijiazhuang, China
  • 6Department of Endocrinology, Heibei Yiling Hospital, Shijiazhuang, China
  • 7Guangzhou University of Traditional Chinese Medicine, Shenzhen Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China

A Corrigendum on
Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Jinlida Granules on Metabolic Syndrome in Patients With Abnormal Glucose Metabolism

by Jin, D., Hou, L., Han, S., Chang, L., Gao, H., Zhao, Y., et al. (2020). Front. Endocrinol. 11:415. doi: 10.3389/fendo.2020.00415

In the original article, there was an error in the “Inclusion Criteria” section. The authors wish to correct this to:

Inclusion Criteria

1. Subjects are between 18 and 70 years of age;

2. After the run-in period, subjects should meet the diagnostic criteria for metabolic syndrome (3, 6):

(a) Indispensable indicators:

Abdominal obesity (central obesity): waist circumference in male ≥ 90 cm, female ≥ 85 cm;

(b) Other indicators:

At least two of the following four indicators can diagnose metabolic syndrome:

① Hyperglycemia: fasting blood glucose (FBG) ≥ 6.1 or 2 h after glucose load (2HPG) ≥ 7.8 mmol/L and/or have been diagnosed as diabetes and received treatments.

② Hypertension: blood pressure ≥ 130/85 mmHg and/or have been confirmed to be hypertension and received related treatments.

③ Fasting TG ≥ 1.70 mmol/L.

④ Fasting HDL-C <1.04 mmol/L.

3. After the run-in period, subjects should meet the diagnostic criteria for impaired glucose tolerance:

(a) Impaired fasting glucose (IGT): FBG < 7.0 mmol/L and 2HPG: 7.8–11.1 mmol/L.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

References

1. International Diabetes Federation. The IDF consensus world-wide definition of the metabolic syndrome. Diabetes Res Clin Pract. (2005) 67:251–7. doi: 10.1016/j.diabres.2004.07.022

CrossRef Full Text | Google Scholar

2. Chinese Diabetes Society. Chinese guidelines for the prevention and treatment of type 2 diabetes (2017 Edition). Chin J Diabetes. (2018) 10:4–67.

Google Scholar

Keywords: Jinlida granules, Chinese medicine, metabolic syndrome, abnormal glucose metabolism, clinical trial

Citation: Jin D, Hou L, Han S, Chang L, Gao H, Zhao Y, Zhao S, An X, Song G, Piao C, Lian F, Xiao-lin T and Jia Z (2020) Corrigendum: Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Jinlida Granules on Metabolic Syndrome in Patients With Abnormal Glucose Metabolism. Front. Endocrinol. 11:649. doi: 10.3389/fendo.2020.00649

Received: 10 July 2020; Accepted: 10 August 2020;
Published: 03 September 2020.

Edited by:

Hans Ulrich Häring, Tübingen University Hospital, Germany

Copyright © 2020 Jin, Hou, Han, Chang, Gao, Zhao, Zhao, An, Song, Piao, Lian, Xiao-lin and Jia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Fengmei Lian, 694397644@qq.com; Tong Xiao-lin, tongxiaolin66@sina.com; Zhenhua Jia, jiatcm@163.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.